Plaque Psoriasis

Awareness of these data may allow for dermatologists to better care for patients with anogenital pruritus as well as their families.

This analysis was done to verify the hypothesis that psoriatic arthritis is primarily genetically predetermined and distinct from the condition of psoriasis.

These findings highlight clinician versus patient perceptions of chronic pruritus assessment using patient-reported outcome measures.

Individuals with both psoriasis and hypertension have approximately a 2-fold increased mortality risk, which is greater than the mortality risk for psoriasis or hypertension alone.

These data highlight the association between risk of developing polyneuropathy and the presence of psoriasis and psoriatic arthritis.

In this analysis, the investigators looked at the impacts of the IL-23 inhibitor guselkumab on patients with psoriasis.

These data suggest the necessity of additional research to explore seborrheic dermatitis as well as its variations among many diverse groups and populations.

These data highlight several key points about COPD and its prevalence, risk, and incidence among plaque psoriasis patients.

In this clinical quiz, you will test your knowledge of psoriasis guidelines, with special focus on important clinical questions related to management of psoriasis and recent evidence-based recommendations.

This summary of major dermatology news covered in June highlights stories such as late-breaking data at RAD 2024, recent interviews, and recent FDA news.

The case series highlighted here was limited due to smaller numbers of participants, necessitating additional real-world data on bimekizumab for psoriasis.

These real-world findings on tildrakizumab’s use among patients with moderate-to-severe plaque psoriasis highlight the drug’s efficacy regarding high burden symptoms.

In this analysis, disparities associated with race, old age, socioeconomic differences, and rural residence were highlighted as examples.

These findings made comparisons between clinical outcomes of interclass and intraclass switching of biologic treatments among individuals with psoriasis.

These data were identified to expand upon existing information regarding treatment options for facial psoriasis and/or genital psoriasis.

A panel of dermatologists have a comprehensive discussion on exciting developments in the treatment of plaque psoriasis, focusing on treatment approaches, patient monitoring strategies, and recent clinical trial data.

Bruce Strober, MD, PhD, and Linda Stein Gold, MD, provide clinical insights on long-term safety data for deucravacitinib and selecting the right treatment for the right patient.

Dermatologists have a comprehensive discussion on systemic therapies for the treatment of plaque psoriasis, covering monitoring practices, and long term efficacy data for novel oral agent deucravacitinib.

These data suggest that quality of life, assessed by DLQI, may be implemented in determining treatment efficacy among patients with psoriasis.

Linda Stein Gold, MD, and Bruce Strober, MD PhD, discuss classification and monitoring practices for patients with plaque psoriasis.

These data, resulting from a post-hoc analysis, highlighted the musculoskeletal, skin, and nail outcomes among patients with psoriasis and PsA.

This analysis among Japanese patients highlights the potential of apremilast for psoriasis patients not responding to topical therapy who may have limited systemic treatment options.

A meta-analysis shows hand eczema has a moderate-to-severe impact on quality of life and anxiety.

In this systematic review and meta-analysis, the clinical efficacy of glucagon-like peptide 1 receptor agonists was evaluated.

These data highlight rates of biologic treatment discontinuation in younger adult patients versus elderly patients, with comparisons drawn between IL-23 inhibitors and IL-17 inhibitors as well.